To determine how the functional status of p53 affects the synergistic cytotoxicity of rapamycin and cisplatin, we examined whether rapamycin sensitizes both WT and null p53 lung cancer cells (A549 and H1299) to cisplatin. Here, TP53 is linked to lung cancer.